Evaluating Technologies Found Cost Effective at Zero Price

This article explains why some technologies may fail to demonstrate cost effectiveness even when the acquisition price is set to zero, raising both methodological and ethical questions for health technology assessment (HTA) agencies. Learn more here. (Source: Sarah Davis, Dr. Ron Akehurst, Health Policy)

You might also be interested in:

Gaps in Health Data are Barrier to Health Equity 01/14/2021
Invoke a 1980's Law to Lower Cost of Remdesivir for COVID-19,… 08/07/2020
Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020
Matthew McHugh Appointed Director for Health Outcomes and… 02/10/2021
[Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
Stanford Center for Health Education Launches Online Program… 08/11/2020
Employee Health Data Analyses Must Include Race And Ethnicity 12/28/2020